About Personalis
Personalis is a precision oncology company focused on transforming the active management of cancer through advanced genomic technologies. The company develops and commercializes comprehensive genomic sequencing and analysis solutions that enable cancer detection, monitoring, and personalized treatment strategies. Personalis serves the oncology research community, biopharmaceutical companies conducting clinical trials, and healthcare providers seeking to implement precision medicine approaches. Their technology platform combines whole genome, whole exome, and targeted sequencing capabilities with proprietary bioinformatics to deliver deep insights into tumor biology and immune response. The company's solutions support both tissue-based tumor profiling and liquid biopsy applications for minimal residual disease detection and treatment monitoring. By providing highly sensitive and comprehensive genomic analysis, Personalis aims to enable earlier cancer detection, more precise treatment selection, and better patient outcomes. Their platform is designed to support the full continuum of cancer care from initial diagnosis through treatment monitoring and surveillance for recurrence.
Clinical Focus
Medical conditions and clinical areas addressed by Personalis.
Who It Serves
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.